Cat. No. Name Size Price Add Cart
KI1128DMXAA5 mg$192
DMXAA25 mg$592
DMXAA100 mg$1552

Chemical Characteristic

Product NameDMXAA
SynonymsAS1404, ASA404
CAS No.117570-53-3
Molecular Weight 282.29
FormulaC17H14O4
Chemical Name2-(5,6-dimethyl-9-oxoxanthen-4-yl)acetic acid
Smilesc1(=O)c2cccc(c2oc2c(c(ccc12)C)C)CC(=O)O
Chemical Structure

Biological activities

DMXAA is a competitive inhibitor of the enzyme DT-diaphorase. The Ki of DMXAA is 20 µM against the DT-diaphorase. In addition, DMXAA also partially inhibits cytochrome b5 reductase activity.[1] DMXAA is identified to be a novel antivascular agent. DMXAA has a striking antivascular and in some cases curative effect.[2] DMXAA induces greater TNF production in tumors than in the spleen, liver, or serum. DMXAA induces both of tumor and host cells to express TNF mRNA. [3] Tumors removed 24 hours after treatment with DMXAA (66 or 100 µmol/kg) are found to be hemorrhagic and necrotic.[4] DMXAA is well tolerated at lower doses and DMXAA doesn?? produce drug-related myelosuppression.[5] In vivo, a single i.p. injection of DMXAA at a dose of 20 mg/kg reduces fibroblast growth factor-induced endothelial cell invasion of Matrigel implants in athymic nude mice by nearly 100%.[6]

Protocols

In vivo DMXAA is dissolved in 5% sodium bicarbonate.[6]

References

[1] Phillips RM. et al. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development. Biochem Pharmacol. 1999, 58(2): 303-310.
[2] Baguley BC. Antivascular therapy of cancer: DMXAA.Lancet Oncol. 2003, 4(3): 141-148.
[3] Joseph WR, et al. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res. 1999, 59(3): 633-638.
[4] Ching LM, et al. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.Cancer Res. 1999, 59(14): 3304-3307.
[5] Jameson MB, et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer. 2003, 88(12): 1844-1850.
[6] Cao Z, et al. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res. 2001, 61(4): 1517-1521.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.
KareBayTM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.